Search for Clinical Trial Results

Scleroderma, Diffuse - 20 Studies Found
Status | Study |
Completed |
Study Name: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis Condition: Scleroderma, Diffuse Date: 2007-01-29 Interventions: Drug: N-acetylcysteine (NAC) |
Recruiting |
Study Name: Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Condition:
|
Recruiting |
Study Name: Scleroderma Registry & Repository at the Hospital for Special Surgery Condition: Scleroderma Date: 2012-08-01 |
Terminated |
Study Name: Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis Condition: Scleroderma, Systemic Date: 2007-01-03 Interventions:
|
Completed |
Study Name: Nilotinib in the Treatment of Systemic Sclerosis Condition: Systemic Sclerosis Date: 2010-07-01 Interventions: Drug: Nilotinib (Tasigna) Patients will be treated with Nilotinib 400 mg two times a day for 6 months. |
Active, not recruiting |
Study Name: Taking Charge of Systemic Sclerosis Condition: Scleroderma Date: 2015-05-22 Interventions:
|
Completed |
Study Name: Morbidity and Mortality Follow Up for the Scleroderma Lung Study Condition: Scleroderma Date: 2013-01-04 Interventions: Other: Followup survey |
Completed |
Study Name: Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Condition: Systemic Sclerosis Date: 2007-11-07 Interventions: Drug: Imatinib Mesylate In initial phase, patients will be treated with Gleevec 400 mg daily for 12 mont |
Completed |
Study Name: Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis Condition: Systemic Sclerosis Date: 2008-04-25 |
Recruiting |
Study Name: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis Condition: Scleroderma Date: 2012-06-18 Interventions: Drug: Campath Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the incl |